A streptococcal prophage lytic enzyme lys733 and its application

By cloning and expressing the streptococcal prophage lys733 from the genome of Streptococcus mastitis, the problem of lack of broad-spectrum antibacterial agents in the prior art is solved, and effective antibacterial treatment of streptococci related to dairy cow mastitis is achieved. Provides low-cost, high-active antibacterial solutions.

CN116355887BActive Publication Date: 2024-11-22LINYI UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310549444.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-05-16
Publication Date
2024-11-22
Estimated Expiration
2043-05-16

AI Technical Summary

Technical Problem

The prior art has not effectively developed broad-spectrum antibacterial agents for the prevention and control of streptococcal infections, especially multiple streptococcal infections related to dairy cow mastitis, and the isolation of streptococcal phages is difficult, resulting in the related phages and phage-derived Lysis enzymes are reported fewer.

Method used

Streptococcus prophage lys733 was cloned from the Streptococcus HB-4 genome, and soluble lysase was induced to express through prokaryotic expression. Gene cloning was performed using Bam HI and Kpn I double enzyme cleavage, and recombinant expression vectors were used. Expressed in E. coli and purified by Ni+ affinity chromatography to obtain products with clear enzymatic activity and physical and chemical properties.

Benefits of technology

The obtained streptococcal prophage lys733 has a specific antibacterial effect on Streptococcus alactis and Streptococcus adenosine, providing the basis for preventing and treating mastitis in dairy cows. It has low production cost and strong activity, and is suitable for promotion and application.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116355887B_ABST
    Figure CN116355887B_ABST
Patent Text Reader

Abstract

The present invention discloses a streptococcal prophage lytic enzyme Lys733 and its application. It belongs to the field of bioengineering technology. The present invention clones the streptococcal prophage lytic enzyme Lys733 from the genome of Streptococcus uberis HB‑4, and adopts a prokaryotic expression method to induce the expression of a soluble lytic enzyme. The streptococcal prophage lytic enzyme Lys733 has a relatively specific antibacterial effect on Streptococcus agalactiae and Streptococcus dysgalactiae in the Streptococcus genus that can cause mastitis in dairy cows, laying a foundation for the prevention and treatment of the above-mentioned bacterial infections.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of bioengineering, and more specifically to a streptococcal prophage lytic enzyme lys733 and an application thereof. Background Art

[0002] Streptococcus bacteria are Gram-positive bacteria that are widely distributed in nature, in human and animal feces, and in the nasopharynx of healthy people. They include a wide variety of pathogenic bacteria. Bacteria such as Streptococcus dysgalactiae, Streptococcus agalactiae, and Streptococcus uberis that infect cattle can cause symptoms such as mastitis in dairy cows, causing huge losses to the livestock breeding industry. The emergence of antibiotics has brought streptococcal infections under certain control. However, with the irregular use of antibiotics in the livestock breeding industry, their drug resistance has gradually increased. The resulting multidrug-resistant bacteria have no available antibiotics for treatment. Therefore, there is an urgent need to develop a new class of antimicrobial drugs or antimicrobial agents for the prevention and control of streptococcal infections.

[0003] Bacteriophages are viruses that can infect prokaryotic microorganisms such as bacteria and archaea. They can quickly lyse bacteria through the "perforin-lyase" binary system. Therefore, bacteriophages and their derived lyases can be used as alternative antibacterial agents to antibiotics. The lysis spectrum of bacteriophages is generally narrow, and their application is limited because bacteria can quickly evolve resistance to surface receptors. However, lyases derived from bacteriophages have a relatively wide lysis spectrum and can be used as an efficient and safe natural antibacterial agent for the prevention and control of drug-resistant pathogenic bacteria. Phage lytic enzymes have the following advantages when used as antimicrobial agents: (1) they can specifically and rapidly kill host bacteria; (2) lytic enzymes act on the peptidoglycan on the surface of bacteria. Since peptidoglycan is a key component of the cell wall and is highly conserved within the species, lytic enzymes exhibit a broader spectrum of lytic activity, which also determines that it is more difficult for bacteria to develop resistance to lytic enzymes; (3) when lytic enzymes are used to treat animals infected with pathogenic bacteria, the host animals will produce antibodies against them, but the active center of the lytic enzyme is generally not an antigenic epitope exposed on the surface, so antibodies against the lytic enzyme will not weaken its lytic and bactericidal effect; (4) The combination of lytic enzymes and other antimicrobial agents such as antibiotics has a synergistic antibacterial effect, which can not only broaden the lytic spectrum, but also more effectively exert antibacterial activity and reduce the probability of bacteria developing resistance.

[0004] For diseases caused by various streptococcal infections related to bovine mastitis, no broad-spectrum and effective streptococcal phage lytic enzymes have been developed and applied to the prevention and control of streptococcal infections. Due to the difficulty in isolating virulent streptococcal phages, there are few reports on related phages and phage-derived lytic enzymes.

[0005] In summary, how to provide a broad-spectrum and effective streptococcal phage lytic enzyme is a problem that those skilled in the art need to solve urgently. Summary of the invention

[0006] In view of this, the present invention provides a streptococcal prophage lytic enzyme lys733 and its application. The present invention found that there are many prophages in the genomes of Streptococcus agalactiae, Streptococcus dysgalactiae and Streptococcus uberis, which can cause mastitis in dairy cows, and the phage lytic enzyme in the prophage genome is a potential antibacterial protein that has not yet been explored.

[0007] In order to achieve the above object, the present invention adopts the following technical solution:

[0008] A streptococcal prophage lytic enzyme lys733, the amino acid sequence of which is shown in SEQ ID NO.1.

[0009] MTINTEQAIAWMAARQGKVTYSMARRDGASSYDCSSSIYYALRSAGASDNGWAVNTEYEHDWLVKNGYQLVAENELLYPKRGDIFVWGKRGYSAGAGGHTGMFVDDSNIIHCNYGYNGITV NDYNQIWYANGQPYEYLYRYIGSGLAPVNQQAVISQFERELDVNTPLSNSTMPYYEATISEDYYVESKPDANSEDKELLVAGTRVRVYEKINGWARINAPQSNQWVEDSYLIDATDM, SEQ ID NO.1.

[0010] A gene encoding the streptococcal prophage lytic enzyme lys733, the nucleotide sequence of which is shown in SEQ ID NO.2.

[0011] atgacaattaacacagaacaagctatagcgtggatggctgcaagacaaggcaaggtcacttactccatggctcggcgtgatggtgcatcatcttatgactgctcaagctcaatttattacgctttgcgttcggctggtgcatctgataatggctgggcggtcaacactgagtatgagcatgattggttagtcaagaacggctatcaattggttgctgagaatgagttgctttatcccaaacgtggtgatatttttgtttggggtaagcgtggttactcagcaggcgctggtggtcatactgggatgttcgtggatgatagcaatatcatccactgtaattatggctacaacggaattacagtaaatgactataaccagatttggtatgccaacgggcaaccgtatgagtatctatacagatacataggttcgggattagcaccagttaatcagcaagcggtcatctcacaatttgagagagagcttgatgttaacactccactaagtaattcaacgatgccttattatgaggcaacgatttcagaggattactacgttgagtcaaaacctgatgcaaattctgaggataaagagttgttagttgctggcaccagagtcagagtatacgaaaaaatcaatggttgggcacgcatcaatgcgcctcaatcaaatcagtgggtagaagatagctatctaatcgacgcaaccgatatg, SEQ ID NO.2。

[0012] Furthermore, the primers for amplifying the said gene are as follows:

[0013] Lys733-F: aggagatataccatgggatccatgacaattaacacagaacaa, SEQ ID NO.3;

[0014] Lys733-R: aaaatacaggttttcggtacccatatcggttgcgtcgat, SEQ ID NO.4。

[0015] The preparation method of the above-mentioned streptococcal prophage lytic enzyme lys733 comprises the following specific steps:

[0016] (1) Using the genome of Streptococcus uberis HB-4 as a template, the nucleotide sequence of the streptococcal prophage lytic enzyme lys733 was amplified;

[0017] (2) cloning the nucleotide sequence obtained in step (1) into an expression vector to obtain a recombinant expression vector;

[0018] (3) transforming the recombinant expression vector obtained in step (2) into competent Escherichia coli cells to obtain recombinant engineered bacteria;

[0019] (4) Using recombinant engineered bacteria to induce the expression of Streptococcus prophage lytic enzyme lys733;

[0020] (5) Extract and purify the streptococcal prophage lytic enzyme Lys733 obtained in step (4).

[0021] Beneficial effects achieved: The method of the present invention can obtain a large number of products with clear enzyme activity and physicochemical properties. The product production cost is low and the product activity is strong, which can meet the production needs of popularization and application.

[0022] Furthermore, in the nucleotide sequence cloning process in step (2), double restriction enzyme digestion with Bam HI and Kpn I is used.

[0023] Furthermore, the expression vector in step (2) is pEC, with a 6xHis tag at the C-terminus and a T7 lac promoter, and Ni + Affinity chromatography purification. The expression vector may also be selected from other vectors suitable for expressing foreign genes in E. coli, such as pET series, pGEX series, pMAL series or pBAD series.

[0024] Furthermore, the engineering bacteria is Escherichia coli BL21 (DE3), and can also be expression host bacteria such as Escherichia coli Rosseta.

[0025] Furthermore, the inducing agent used to induce expression in step (4) is IPTG, the induction concentration is 0.5 mmol / L, and the induction time is 16 h.

[0026] Furthermore, the culture temperature of the engineered bacteria is 37°C and the induction expression temperature is 25°C.

[0027] A recombinant expression vector, wherein the recombinant expression vector is an expression vector containing the above gene.

[0028] A host cell containing the above recombinant expression vector.

[0029] The above-mentioned streptococcal prophage lytic enzyme lys733 is used in the following aspects:

[0030] 1) Application of the streptococcal prophage lytic enzyme lys733 in specific lytic streptococci;

[0031] 2) Application of the streptococcal prophage lytic enzyme lys733 in the preparation of biological preparations for lytic streptococci;

[0032] 3) Use of the streptococcal prophage lytic enzyme lys733 in the preparation of a drug for preventing or treating bovine mastitis.

[0033] Furthermore, the streptococci are Streptococcus agalactiae and Streptococcus dysgalactiae.

[0034] It can be seen from the above technical solution that compared with the prior art, the present invention has the following beneficial effects: the present invention clones the prophage lytic enzyme lys733 of Streptococcus uberis from the genome of Streptococcus HB-4, and uses prokaryotic expression to induce the expression of soluble lytic enzyme. The prophage lytic enzyme lys733 of Streptococcus uberis has a relatively specific antibacterial effect on Streptococcus agalactiae and Streptococcus dysgalactiae in the Streptococcus genus that can cause mastitis in dairy cows, laying a foundation for the prevention and treatment of diseases infected by the above bacteria. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0036] Figure 1 The SDS-PAGE result of prokaryotic expression and purification of Streptococcus prophage lytic enzyme lys733 in Example 3 of the present invention is shown, wherein M is a standard protein molecular weight marker; Lane 1 is the whole protein of the expression engineering strain transferred into the empty plasmid; Lane 2 is the whole protein of the recombinant engineering strain; Lanes 3 and 4 are the purification results of Streptococcus prophage lytic enzyme lys733;

[0037] Figure 2 It is the domain of the streptococcal prophage lytic enzyme lys733 in Example 4 of the present invention, wherein NLPC / P60 is the lytic domain and SH3-3 is the binding domain; NLPC / P60 starts at the numerical value 4 and ends at the numerical value 145 in the protein sequence; SH3-3 starts at the numerical value 165 and ends at the numerical value 228 in the protein sequence;

[0038] Figure 3This is a diagram of the three-dimensional structure of the streptococcal prophage lytic enzyme lys733 predicted by AlphaFold in Example 4 of the present invention, wherein the red part is the NLPC / P60 domain and the blue part is the SH3-3 domain;

[0039] Figure 4 This is a graph showing the in vitro antibacterial effect of the Streptococcus prophage lytic enzyme lys733 on Streptococcus dysgalactiae SD24 in Example 5 of the present invention;

[0040] Figure 5 This is a diagram showing the effect of the streptococcal prophage lytic enzyme Lys733 acting on the bacterial solution of Streptococcus dysgalactiae SD24 for 1 hour in Example 5 of the present invention, wherein the left side shows the bacterial solution without the addition of the lytic enzyme Lys733, and the right side shows the state of the bacterial solution after the addition of the lytic enzyme Lys733 with a final concentration of 400 μg / mL for 1 hour. DETAILED DESCRIPTION

[0041] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0042] The drugs required for the present invention are conventional experimental drugs, which are purchased from commercial channels; the experimental methods not mentioned are conventional experimental methods and will not be described in detail here.

[0043] Example 1 PCR amplification and recovery

[0044] The nucleotide sequence shown in SEQ ID NO. 2 was amplified using primer pair lys733-F / R.

[0045] The lys733-F sequence is shown in SEQ ID NO. 3, and the lys733-R sequence is shown in SEQ ID NO. 4. The primer sequence contains a homology arm fragment at the connection site of the expression vector.

[0046] atgacaattaacacagaacaagctatagcgtggatggctgcaagacaaggcaaggtcacttactccatggctcggcgtgatggtgcatcatcttatgactgctcaagctcaatttattacgctttgcgttcggctggtgcatctgataatggctgggcggtcaacactgagtatgagcatgattggttagtcaagaacggctatcaattggttgctgagaatgagttgctttatcccaaacgtggtgatatttttgtttggggtaagcgtggttactcagcaggcgctggtggtcatactgggatgttcgtggatgatagcaatatcatccactgtaattatggctacaacggaattacagtaaatgactataaccagatttggtatgccaacgggcaaccgtatgagtatctatacagatacataggttcgggattagcaccagttaatcagcaagcggtcatctcacaatttgagagagagcttgatgttaacactccactaagtaattcaacgatgccttattatgaggcaacgatttcagaggattactacgttgagtcaaaacctgatgcaaattctgaggataaagagttgttagttgctggcaccagagtcagagtatacgaaaaaatcaatggttgggcacgcatcaatgcgcctcaatcaaatcagtgggtagaagatagctatctaatcgacgcaaccgatatg, SEQ ID NO.2.

[0047] aggagatataccatgggatccatgacaattaacacagaacaa, SEQ ID NO.3.

[0048] aaaatacaggttttcggtacccatatcggttgcgtcgat, SEQ ID NO.4.

[0049] Reaction system: 2×Phanta Mix Master Buffer 25 μL, template DNA 1 μL, upstream and downstream primers each 2 μL, ddH 2 O 20 μL.

[0050] Reaction conditions: pre-denaturation at 95°C for 3 min, start cycle: denaturation at 95°C for 15 s, annealing at 60°C for 15 s, extension at 72°C for 90 s, 30 cycles, and final extension at 72°C for 10 min.

[0051] The PCR amplification products were detected by 1% agarose gel electrophoresis, and the target fragments amplified by PCR were recovered using the Novagen gel recovery kit.

[0052] Example 2 Connection of recombinant expression plasmid and transformation of competent cells

[0053] The expression vector was double-digested with enzymes. The digestion system was: pEC plasmid 10 μL, Bam HI 1 μL, Kpn I 1 μL, 10×MBuffer 2 μL, ddH 2 O 6μL. 37℃, water bath for 4h, the enzyme digestion system was verified by 1% agarose gel electrophoresis, gel recovery, and the vector with sticky ends was obtained.

[0054] According to the concentration of the target gene PCR gel recovery product and the plasmid after enzyme digestion, determine the 20μL one-step cloning and connection system: 2μL target gene, 2μL plasmid enzyme digestion product, 4μL 5×CE II Buffer, ddH 2 O12μL. 37℃, connect for 30min.

[0055] Add 10 μL of the ligation product to 100 μL of E. coli DH5α competent cells, mix gently, and place on ice for 30 min. Then heat shock at 42°C for 90 s, and quickly place on ice for 2 min. Add 890 μL of LB medium and culture at 37°C with shaking for 1 h. After centrifugation at 5000 rpm for 5 min, discard 900 μL of the supernatant, use the remaining 100 μL of the resuspended bacterial solution, and evenly spread it on the solid LB medium containing Kan (final concentration 50 μg / mL), and culture it inverted in a 37°C incubator overnight.

[0056] A single colony on the Kan plate was picked up and inoculated into LB liquid culture medium containing Kan for cultivation. After obtaining the bacterial suspension, the positive bacterial suspension was identified by PCR. At the same time, the PCR identification system was sent to Shanghai Sangon Biotechnology Co., Ltd. for sequencing, and the sequencing results were compared with the target gene sequence.

[0057] After the correctly sequenced recombinant DH5α strain was cultured overnight, the recombinant plasmid was extracted using the Novozymes plasmid extraction kit.

[0058] Take 10 μL of recombinant plasmid and add it to 100 μL of E. coli BL21 competent cells, mix well and place on ice for 30 minutes. Then heat shock at 42℃ for 90 seconds and quickly place on ice for 2 minutes. Add 890 μL of LB medium and culture at 37℃ with shaking for 1 hour. Take 100 μL of bacterial solution and evenly spread it on solid LB medium containing Kan (final concentration 50 μg / mL) and culture it upside down in a 37℃ incubator overnight.

[0059] Example 3 Prokaryotic expression and purification of Streptococcus prophage lytic enzyme Lys733

[0060] Pick a single colony on the Kan plate and inoculate it into LB liquid medium containing Kan for cultivation. After obtaining a bacterial suspension, identify the positive bacterial suspension by PCR. Transfer the positive bacterial suspension to LB liquid medium and culture at 37℃ with shaking until OD 600 After about 0.6 to 0.8, add IPTG with a final concentration of 0.5mmol / L and shake at 25℃ overnight to induce expression. Use the expression engineering bacteria transferred with empty plasmid as negative control. After the recombinant engineering bacteria are expanded and cultured, induce expression, and then use ultrasonic disruption to lyse the bacteria. After centrifugation at 12000rpm and 4℃ for 10min, remove the supernatant and perform SDS-PAGE electrophoresis analysis. The results are as follows Figure 1 As shown, compared with the expression engineering bacteria transferred with an empty plasmid (lane 1), the recombinant engineering bacteria showed a thicker band at 30 KDa (lane 2).

[0061] The cells were resuspended in 50 mM imidazole solution, lysed by ultrasonication, and the supernatant was taken and purified by Ni + The affinity chromatography column is used to purify the lytic enzyme protein. The column is equilibrated with the equilibrium solution for 2 to 3 times, and then the supernatant is loaded onto the column multiple times to allow the target protein to interact with the affinity chromatography Ni. + The filler was fully bound and washed 6 times with 50mM imidazole to remove the impurities. Then 200mM imidazole was used to elute the target protein. The results of protein purification are shown in Figure 1 Lanes 3 and 4 show the results.

[0062] Example 4 Analysis of the physicochemical properties of Streptococcus prophage lytic enzyme lys733

[0063] Number of amino acids: 238.

[0064] Relative molecular mass: 26894.60.

[0065] Theoretical pI: 4.63.

[0066] Amino Acid Composition:

[0067]

[0068]

[0069] Total number of negatively charged residues (Asp+Glu): 30.

[0070] Total number of positively charged residues (Arg+Lys): 18.

[0071] Atomic composition:

[0072]

[0073] Molecular formula: C 1192 H 1775 N 319 O 379 S 8

[0074] Total number of atoms: 3673.

[0075] Extinction coefficient:

[0076] Extinction coefficient is expressed in M -1 cm -1 The unit is measured in water at 280nm.

[0077] The extinction coefficient is 71280.

[0078] The absorbance value of 0.1% (=1 g / l) is 2.650.

[0079] Estimated half-life:

[0080] The N-terminal of the protein sequence is methionine (Met).

[0081] The estimated half-life is 30 hours (mammalian reticulocytes, in vitro);

[0082] >20 hours (yeast, in vivo);

[0083] >10 hours(Escherichia coli,invivo).

[0084] Instability Index:

[0085] The instability index (II) was calculated to be 32.06.

[0086] This indicates that the protein classification is stable.

[0087] The aliphatic index is 70.13.

[0088] The overall average hydrophilicity (GRAVY) is -0.546.

[0089] Domain

[0090] The amino acid sequence of Streptococcus prophage lytic enzyme lys733 (SEQ ID NO.1) was submitted to the Pfam server (http: / / pfam.xfam.org / ) for domain prediction. The results showed that the domain of Streptococcus prophage lytic enzyme lys733 included an N-terminal NLPC / P60 lytic domain and a C-terminal SH3-3 binding domain.

[0091] Further, the N-terminal NLPC / P60 cleavage domain is from position 4 to position 145 of the amino acid sequence shown in SEQ ID NO.1, and the C-terminal SH3-3 binding domain is from position 165 to position 228 of the amino acid sequence shown in SEQ ID NO.1. Figure 2 ).

[0092] MTINTEQAIAWMAARQGKVTYSMARRDGASSYDCSSSIYYALRSAGASDNGWAVNTEYEHDWLVKNGYQLVAENELLYPKRGDIFVWGKRGYSAGAGGHTGMFVDDSNIIHCNYGYNGITV NDYNQIWYANGQPYEYLYRYIGSGLAPVNQQAVISQFERELDVNTPLSNSTMPYYEATISEDYYVESKPDANSEDKELLVAGTRVRVYEKINGWARINAPQSNQWVEDSYLIDATDM, SEQ ID NO.1.

[0093] Use the AlphaFold Colab website ( https: / / colab.research.google.com / github / sokr yp ton / ColabFold / blob / main / AlphaFold2.ipynb#scrollTo=AzIKiDiCaHAn) The three-dimensional structure prediction of Streptococcus prophage lytic enzyme lys733 was performed, and its amino acid sequence (SEQ ID NO.1) was submitted. After downloading the prediction results, the domain was drawn using pymol software. The results are as follows Figure 3 shown.

[0094] Example 5 In vitro antibacterial activity determination and lysis spectrum determination of Streptococcus prophage lytic enzyme Lys733

[0095] Streptococcus dysgalactiae SD24 was cultured in BHI medium until the logarithmic phase. After centrifugation, the precipitate was washed twice with Tris-HCl (pH 7.5), and then the bacteria were resuspended with Tris-HCl and the OD was adjusted. 600100 μL of concentrated bacterial solution was mixed with 100 μL of Streptococcus prophage lytic enzyme lys733 at different concentrations (0, 400, 600, 800, 1000 μg / mL) in a 96-well plate to adjust the OD of the mixed solution to 0.6. 600 The value is about 0.6, and the final concentrations of Streptococcus prophage lytic enzyme lys733 are 0, 200, 300, 400, and 500 μg / mL respectively. 100 μL of concentrated bacterial solution and 100 μL of Tris-HCl mixed solution were used as controls. Three parallels were placed in a multifunctional microplate reader and cultured at 37°C. The OD was measured every 10 minutes. 600 Numerical value, plotting OD 600 A curve that changes over time.

[0096] The results are as follows Figure 4 As shown, the OD of the groups treated with different concentrations of Streptococcus prophage lytic enzyme Lys733 600 The value showed a gradual downward trend, the bacterial solution gradually became clear, and the OD without adding streptococcal prophage lytic enzyme lys733 600 The values ​​were basically unchanged. Among them, the downward trend of the 200 or 300 μg / mL lyase group was slightly worse; when the lyase concentration was ≥400 μg / mL, OD 600 The decrease in values ​​tended to be consistent, indicating that the application concentration of 400 μg / mL could achieve the best antibacterial effect.

[0097] A total of 12 strains, including Streptococcus uberis, Streptococcus dysgalactiae, Streptococcus agalactiae, Staphylococcus aureus, Listeria monocytogenes, Escherichia coli and Pseudomonas aeruginosa, were used for the determination of the cleavage spectrum of the prophage lytic enzyme lys733 of Streptococcus. The strains to be tested were cultured at 37°C until the mid-logarithmic growth period, and the bacterial solution was centrifuged and the precipitate was washed twice with Tris-HCl (pH 7.5), and then the bacteria were resuspended with Tris-HCl and the OD was adjusted. 600 100 μL of concentrated bacterial solution was mixed with 100 μL of 800 μg / mL Streptococcus prophage lytic enzyme Lys733 in a 96-well plate to adjust the OD of the mixture to 0.6. 600 The value is about 0.6, the final concentration of Streptococcus prophage lytic enzyme lys733 is 400μg / mL, 100μL concentrated bacterial solution and 100μL Tris-HCl mixed solution are used as controls, 3 parallels per group, placed in a multifunctional microplate reader and cultured at 37℃. OD is measured at 0h and 1h 600 Numerical value, calculate OD 600 The value decreases in proportion to OD 600 A decrease in the value ratio of >50% indicated complete lysis, and the lysis spectrum of the streptococcal prophage lytic enzyme lys733 was determined.

[0098] The lysis spectrum results are shown in Table 1. Streptococcus prophage lytic enzyme Lys733 has lysis effects on Streptococcus agalactiae and Streptococcus dysgalactiae in the tested Streptococcus genus, but has no lysis effect on Streptococcus uberis, Staphylococcus aureus, Listeria monocytogenes and Gram-negative bacteria such as Escherichia coli and Pseudomonas aeruginosa. This result shows that Streptococcus prophage lytic enzyme Lys733 has a more specific antibacterial ability.

[0099] Table 1 Results of determination of cleavage spectrum of Streptococcus prophage lytic enzyme Lys733

[0100]

[0101] Note: “+” represents lysis ability, “-” represents no lysis ability.

[0102] The various embodiments in this specification are described in a progressive manner, and each embodiment focuses on the differences from other embodiments. The same or similar parts between the various embodiments can be referenced to each other.

[0103] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. Application of Streptococcus prophage lytic enzyme LYS733 in the following aspects: 1) Application of the streptococcal prophage lytic enzyme lys733 in the preparation of biological preparations for lytic streptococci; The streptococci are Streptococcus agalactiae and Streptococcus dysgalactiae; 2) Use of the streptococcal prophage lytic enzyme lys733 in the preparation of a drug for preventing or treating bovine mastitis caused by Streptococcus agalactiae and Streptococcus dysgalactiae; The amino acid sequence of the streptococcal prophage lytic enzyme lys733 is shown in SEQ ID NO.1.